Glenmark RYALTRIS reaches 58 markets; AUMOLERTINIB eyes H2 FY27

Glenmark has commercialized RYALTRIS in 58 markets, with secondary sales growing more than 30% year-on-year, and anticipates AUMOLERTINIB’s first commercial launch in H2 FY27 after filing marketing authorization applications in 13 markets as of September 2026. The portfolio update combines established product expansion with regulatory and clinical milestones.

How far has Glenmark expanded RYALTRIS internationally?

Glenmark had commercialized RYALTRIS in 58 markets and launched it in Brazil during Q2 FY27. Glenmark expects another 10 market launches in upcoming quarters, although the presentation does not identify the countries or give country-specific launch dates. The product’s reported secondary-sales growth was more than 30% year-on-year, without an underlying sales-value disclosure.

Brazil is part of Glenmark’s Emerging Markets region, where Q2 FY27 revenue rose 33.2% year-on-year to Rs 876.9 crore from Rs 658.5 crore in Q2 FY26. Glenmark also said RYALTRIS was gaining share across key Middle East and Africa markets. In Asia-Pacific, Glenmark attributed strong secondary-sales growth to Dermatology and Respiratory, but did not separate RYALTRIS revenue from regional revenue.

Emerging Markets exceeded Europe in Q2 FY27 revenue, at Rs 876.9 crore versus Rs 792 crore, and also grew faster, at 33.2% versus 6.2%. For H1 FY27, Emerging Markets revenue was Rs 1,607.3 crore, up 30.6% from Rs 1,230.6 crore, while Europe reached Rs 1,539.2 crore, up 8.9% from Rs 1,413.8 crore. Glenmark specifically highlighted RYALTRIS expansion in Brazil and Middle East and Africa markets.

What is Glenmark planning for RYALTRIS after 58 markets?

Glenmark plans 10 additional RYALTRIS market launches in upcoming quarters following the Brazil launch in Q2 FY27. This is a stated plan rather than a completed rollout, and Glenmark did not disclose the regulatory status, expected timing or sales potential of each of the 10 markets. The more-than-30% year-on-year secondary-sales growth figure remains the disclosed commercial measure for RYALTRIS.

Glenmark is pursuing the RYALTRIS rollout alongside market-access and scientific-engagement initiatives in Europe, where it reported Q2 FY27 revenue of Rs 792 crore. RYALTRIS and WINLEVI gained further traction across key European markets, according to the presentation. Glenmark did not provide product-level revenue, so the relative contribution of either product to Europe’s 6.2% Q2 FY27 growth cannot be calculated.

WINLEVI provides a separate measure of commercial access in the innovative portfolio. Glenmark said WINLEVI had launched in several European markets, including the Nordics, Central and Eastern Europe, Spain and Portugal, and had achieved formulary status covering about 40% of United Kingdom market potential. That 40% coverage refers to WINLEVI, not RYALTRIS, and does not indicate RYALTRIS reimbursement coverage.

Which Glenmark product has the nearest disclosed first launch?

AUMOLERTINIB has the nearest disclosed first commercial launch, which Glenmark anticipates during H2 FY27. As of September 2026, Glenmark had submitted marketing authorization applications in 13 markets. The presentation does not name the proposed first-launch market, provide an approval decision date or state the product’s expected revenue contribution.

QiNHAIYO had a larger filing footprint, with marketing authorization applications submitted in 24 countries, compared with 13 markets for AUMOLERTINIB. QiNHAIYO had also initiated early-access programs or Named Patient Programs in nine markets and received its first market regulatory approval in the Dominican Republic. Glenmark did not disclose a date for a broader commercial launch of QiNHAIYO.

The two products therefore have different disclosed markers of progress. QiNHAIYO had filings in 24 countries, nine early-access or Named Patient Programs and one approval, while AUMOLERTINIB had filings in 13 markets and an explicit first-launch expectation for H2 FY27. Glenmark gave no pricing, sales forecast or market-by-market approval target for either asset.

What progress has Glenmark reported for trastuzumab rezetecan and earlier assets?

Glenmark submitted marketing authorization applications for trastuzumab rezetecan in two markets and initiated a Phase 3 trial in India in platinum-resistant ovarian cancer, or PROC. Glenmark also received regulatory approvals to begin enrolment in Australia. These are filing and trial-enrolment milestones, rather than evidence of commercial approval or launch in either of the two application markets.

Glenmark did not disclose enrolment targets, completion timing, efficacy results or a commercial-launch schedule for the Phase 3 PROC program. The Australian approval permits enrolment activity, while the two marketing authorization applications relate to separate regulatory pathways. The presentation does not state whether the India trial and the two applications concern the same prospective launch sequence.

For ISB 2001, also called ABBV-2001, more than 170 subjects had been dosed in the TRIgnite-1 Phase 1 study, including 42 in dose escalation and more than 130 in dose expansion. Glenmark said updated Phase 1 data had been accepted for oral presentation at the 2026 American Society of Hematology meeting. Separately, IGI intends to submit an investigational new drug application for ISB 2301 by the end of calendar 2026, while ISB 2302 and ISB 2501 remain in early preclinical development.

Conclusion

Glenmark’s update shows different stages of execution across its innovative portfolio. RYALTRIS has the broadest disclosed commercial reach at 58 markets and more than 30% year-on-year secondary-sales growth, while Emerging Markets revenue rose 33.2% to Rs 876.9 crore in Q2 FY27. AUMOLERTINIB, QiNHAIYO and trastuzumab rezetecan are progressing through different combinations of applications, approval, access programs and clinical work.

The next disclosed items to watch are 10 planned RYALTRIS launches in upcoming quarters, AUMOLERTINIB’s anticipated first commercial launch in H2 FY27, and IGI’s intended ISB 2301 investigational new drug application by the end of calendar 2026. For trastuzumab rezetecan, Glenmark has disclosed Australian enrolment approval but no trial readout or market-launch timetable.